U.S. weighs next steps for Johnson & Johnson COVID-19 shot amid reports of clotting

U.S. health officials are weighing next steps as they investigate a handful of unusual blood clots in people who received Johnson & Johnson's COVID-19 vaccine a one-dose shot that many countries were eagerly awaiting to help speed virus protection.

It's not clear if the exceedingly rare reports so far, six cases out of more than 7 million inoculations in the U.S. really are linked to the J&J vaccine. But the government recommended a pause in J&J vaccinations on Tuesday, just a week after European regulators declared that such clots are a rare but possible risk with the AstraZeneca vaccine, a shot made in a similar way but not yet approved for use in the U.S.

The clots occurred in strange places, in veins that drain blood from the brain, and in people with abnormally low levels of clot-forming platelets. The six cases raised an alarm bell because that number is at least three times more than experts would have expected to see even of more typical brain-drainage clots, said Dr. Tom Shimabukuro of the Centers for Disease Control and Prevention.

The CDC called its advisers together Wednesday for a public debate about how to handle the J&J vaccine while authorities nail down exactly what's happening.

"What we have here is a picture of clots forming in large vessels where we have low platelets," Shimabukuro explained. "This usually doesn't happen," but it's similar to European reports with the AstraZeneca vaccine.

The clot concerns could undermine public confidence in a vaccine many hoped would help some of the hardest-to-reach populations in poor countries or in places like homeless shelters in the U.S.

"We know we are fighting a war against COVID-19," Dr. Peter Marks, the Food and Drug Administration's vaccine chief, said Tuesday. But when it comes to side effects, "we don't, in the United States, have a lot of tolerance for friendly fire."

Health officials recommended the J&J timeout in part to make sure doctors know how to recognize and treat the unusual condition. On Wednesday, the CDC said four of the six women with the unusual clots were treated with a blood thinner named heparin a treatment the government is warning doctors to avoid.

The U.S. set up intensive systems to track the safety of COVID-19 vaccines, knowing that side effects too rare to have occurred in studies of thousands of people could pop up once millions rolled up their sleeves. Shimabukuro said spotting such a rare potential risk amid the nation's huge vaccine rollout "is an example of a success story for vaccine safety."

The setback for J&J comes as the worldwide death toll from COVID-19 approaches 3 million, including more than 560,000 who perished in the U.S., which continues to report tens of thousands of new infections every day and an average of almost 1,000 deaths.

So far, the J&J vaccine has been a minor player in U.S. vaccinations. More than 122 million Americans have received at least one vaccine dose, the vast majority with shots made by Moderna or Pfizer, and nearly 23 per centare fully vaccinated.

Both companies are on track to have delivered 300 million doses each by mid- to late July and federal health authorities stress that there are no signs of the unusual clots with the Moderna and Pfizer vaccines.

Canada has approved the Johnson & Johnson vaccinebut has not yet received any doses.

Prime Minister Justin Trudeau said Tuesday that Canadian officials are closely monitoring the decision by U.S. health authorities.

Trudeau said Canada's immunization campaign can continueat its current pace, even if there are significant delays in deploying the J&J shot, because deliveries of thePfizer, Moderna and AstraZenecaproducts are moreconsistent now,and44 million doses of those three vaccines will be on hand by the end of June.

WATCH | Dr. Theresa Tam reacts to the U.S. decision:

Dr. Tam reacts to Johnson and Johnson COVID-19 vaccine pause in U.S.

3 years ago

Duration 1:29

Chief Public Health Officer Dr. Theresa Tam says the Johnson and Johnson COVID-19 vaccine will go through Health Canada's review process to screen for adverse effects.

European regulators will make their own evaluation

In Europe, many countries have struggled for supply. J&J delayed some of its European deliveries amid the clot evaluation, but Poland said it would use the batch it already has in hand. European medical regulators plan to issue their own evaluation of the J&J clot issue next week.

When those weird clots were spotted after AstraZeneca vaccinations, scientists in Norway and Germany raised the possibility that some people are experiencing an abnormal immune response, forming antibodies that disable their platelets. That's the theory as the U.S. now investigates the J&J reports.

Health officials caution against confusing the normal flu-like symptoms that occur a day or two after many COVID-19 vaccination with the clot concern. The problematic clot symptoms, such as severe headache or severe abdominal pain, have occurred about a week to three weeks after the J&J shot.